Zobrazeno 1 - 10
of 266
pro vyhledávání: '"Lee S. Rosen"'
Autor:
Geoffrey I. Shapiro, Patrick Y. Wen, Keith T. Flaherty, Edward M. Chan, Damien M. Cronier, Martin Frenzel, Lily Q. Li, Palaniappan Kulanthaivel, Ricardo Martinez, Tuan S. Nguyen, Angie D. Fulford, Andrew E. Schade, Richard P. Beckmann, Aejaz Nasir, John F. Hilton, Drew W. Rasco, Muralidhar Beeram, Kyriakos P. Papadopoulos, Leena Gandhi, Jonathan W. Goldman, Anthony W. Tolcher, Sara M. Tolaney, Lee S. Rosen, Amita Patnaik
Supplementary Table 1. Summary of 33 Patients Treated with Abemaciclib in Dose Escalation. Supplementary Table 2. Baseline patient and disease characteristics. Supplementary Table 3. Possibly related treatment-emergent adverse events (>10% all grades
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36991b4fd4f6f7c7f083e22b6e2c0a5d
https://doi.org/10.1158/2159-8290.22531521
https://doi.org/10.1158/2159-8290.22531521
Autor:
Lee S. Rosen, Simon Ashworth, Fang Fang, Y. Nancy Wong, Dale E. Shuster, Diana C. Walton, Eric H. Rubin, Antoinette R. Tan
Purpose: To evaluate the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of eribulin mesylate (E7389), a halichondrin B analogue, administered every 21 days in patients with advanced solid tumors.Experimental Design
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84df5d1c98a1c5ea5b5ab2e556ba300a
https://doi.org/10.1158/1078-0432.c.6517653
https://doi.org/10.1158/1078-0432.c.6517653
Autor:
George D. Demetri, David Grayzel, Emmanuel Normant, Joi Dunbar, Michael Gordon, Suzanne George, Jeffrey A. Morgan, Lee S. Rosen, Rashmi Chugh, Andrew J. Wagner
Supplementary Figure 2 - PDF file 49K, Example Western Blot Showing that IPI 504 above 150 mg/m2 Induces an Increase in Hsp70 in PBLs from GIST Patients PBLs were purified from GIST patient samples, and lysed. Ten microg of protein lysates were run o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1eb57d0feed36c013d4c97c1a10f7420
https://doi.org/10.1158/1078-0432.22449947.v1
https://doi.org/10.1158/1078-0432.22449947.v1
Autor:
George D. Demetri, David Grayzel, Emmanuel Normant, Joi Dunbar, Michael Gordon, Suzanne George, Jeffrey A. Morgan, Lee S. Rosen, Rashmi Chugh, Andrew J. Wagner
Supplementary Table 1 - PDF file 74K, Mean (SD) pharmacokinetic parameters of IPI-504 and metabolites on Cycle 1, Day 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7dbad7695bec95e9a2a536bccd44fa7
https://doi.org/10.1158/1078-0432.22449941
https://doi.org/10.1158/1078-0432.22449941
Autor:
Lee S. Rosen, Simon Ashworth, Fang Fang, Y. Nancy Wong, Dale E. Shuster, Diana C. Walton, Eric H. Rubin, Antoinette R. Tan
Editorial on this Article from Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f1ee5c26ebc43bfec7b5d78f00f53f3
https://doi.org/10.1158/1078-0432.22440303
https://doi.org/10.1158/1078-0432.22440303
Autor:
Marka R. Crittenden, Matthew G. Fury, Israel Lowy, Elizabeth Stankevich, Minjie Feng, Anne Paccaly, Jingjin Li, Rom S. Leidner, Glen J. Weiss, Lee S. Rosen, Richard D. Carvajal, Aung Naing, Silvia C. Formenti, Gerald S. Falchook, Kathleen Moore, Albert C. Lockhart, Melissa L. Johnson, Kyriakos P. Papadopoulos
Combination of all supplementary materials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27800bf8cc320de5b29922a3684ef18a
https://doi.org/10.1158/1078-0432.22476956.v1
https://doi.org/10.1158/1078-0432.22476956.v1
Autor:
John Sarantopoulos, Min Zhu, Poornima Shubhakar, Marilyn Mulay, Monica M. Mita, Alain C. Mita, Shaunita A. Michael, Ian McCaffery, Devalingam Mahalingam, Jill Gilbert, Hongjie Deng, Yuying C. Hwang, Emily Chan, Gregory Friberg, Igor Puzanov, Lee S. Rosen
Purpose: This phase 1b dose-escalation study assessed safety, tolerability, and pharmacokinetics of ganitumab, a fully human monoclonal antibody against the insulin-like growth factor 1 (IGF1) receptor, combined with targeted agents or cytotoxic chem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b92cc2ea087be5d33c3d1a12bd359087
https://doi.org/10.1158/1078-0432.c.6522288
https://doi.org/10.1158/1078-0432.c.6522288
Autor:
George D. Demetri, David Grayzel, Emmanuel Normant, Joi Dunbar, Michael Gordon, Suzanne George, Jeffrey A. Morgan, Lee S. Rosen, Rashmi Chugh, Andrew J. Wagner
Supplementary Figure Legend - PDF file 74K, Supplementary figure legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a1af4e1f0cb128c4c0cfca214c22a6d
https://doi.org/10.1158/1078-0432.22449944
https://doi.org/10.1158/1078-0432.22449944
Autor:
Michaela Banck, James E. Wooldridge, Volker Wacheck, Jay Tuttle, Xuejing Aimee Wang, Tianle Hu, Brian Moser, P. Kellie Turner, Alain P. Algazi, Jonathan W. Goldman, Lee S. Rosen
Table S1. Treatment emergent adverse events regardless of causality in {greater than or equal to}10% of patients; Table S2. Best Overall Response; Table S3. Reasons for Emibetuzumab Discontinuation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f81cf969170c12c35f49188178d97ea
https://doi.org/10.1158/1078-0432.22466984
https://doi.org/10.1158/1078-0432.22466984
Autor:
Marka R. Crittenden, Matthew G. Fury, Israel Lowy, Elizabeth Stankevich, Minjie Feng, Anne Paccaly, Jingjin Li, Rom S. Leidner, Glen J. Weiss, Lee S. Rosen, Richard D. Carvajal, Aung Naing, Silvia C. Formenti, Gerald S. Falchook, Kathleen Moore, Albert C. Lockhart, Melissa L. Johnson, Kyriakos P. Papadopoulos
Purpose:This first-in-human study assessed the safety, tolerability, dose-limiting toxicities (DLT), antitumor activity, and pharmacokinetics of cemiplimab, a monoclonal anti-programmed cell death-1 (PD-1), as monotherapy and in combination with hypo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07b0a7d560bd2f7c8604c5b932ee5173
https://doi.org/10.1158/1078-0432.c.6529538.v1
https://doi.org/10.1158/1078-0432.c.6529538.v1